Integra LifeSciences Holdings
What analysts say
- Buy, sell, or hold?: Analysts generally think investors should hang on to Integra LifeSciences Holdings, with half rating the stock a hold. Analysts like Integra LifeSciences Holdings better than competitor Teleflex overall. Two out of six analysts rate Teleflex a buy compared to nine of 18 for Integra LifeSciences Holdings. Analysts still rate the stock a hold, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $188.9 million in revenue this quarter. That would represent a rise of 5.8% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.69 per share. Estimates range from $0.67 to $0.73.
What our community says
CAPS All-Stars are solidly backing the stock with 91.3% awarding it an "outperform" rating. The community at large agrees with the All-Stars, with 94% assigning it a rating of "outperform." Fools are bullish on Integra LifeSciences Holdings, though the message boards have been quiet lately with only 35 posts in the past 30 days. Even with a robust four out of five stars, Integra LifeSciences Holdings' CAPS rating falls a little short of the community's upbeat outlook.
Integra LifeSciences Holdings' profit has risen year over year by an average of 11.1%. Revenue has now gone up for three straight quarters.
For all our Integra LifeSciences Holdings-specific analysis, including earnings and beyond, add Integra LifeSciences Holdings to My Watchlist.
Motley Fool newsletter services have recommended buying shares of Teleflex. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today
Shares fell after the company's second-quarter results came up short of expectations.
Integra LifeSciences' Stock Split: Why It Accomplished Nothing
Integra LifeSciences' stock split in January. Was it an exercise in futility?
Integra Beats on the Bottom Line
Resistance from payors over spine procedures pressures surgical technology specialist.